Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, Chester JD, Parker AL.

Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29.

2.
3.
4.

Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells.

Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, Costanzo A, Tuosto L.

Mol Cancer Ther. 2008 Jun;7(6):1410-9. doi: 10.1158/1535-7163.MCT-08-0299.

5.

Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines.

Jin X, Fang Y, Hu Y, Chen J, Liu W, Chen G, Gong M, Wu P, Zhu T, Wang S, Zhou J, Wang H, Ma D, Li K.

Oncol Lett. 2017 Jun;13(6):4619-4626. doi: 10.3892/ol.2017.6032. Epub 2017 Apr 13.

6.

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.

Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, Girard L, Martinez ED.

Br J Cancer. 2012 Jan 3;106(1):116-25. doi: 10.1038/bjc.2011.532. Epub 2011 Dec 8.

7.

Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.

Ma J, Li N, Zhao J, Lu J, Ma Y, Zhu Q, Dong Z, Liu K, Ming L.

Oncol Lett. 2017 Jun;13(6):4868-4874. doi: 10.3892/ol.2017.6069. Epub 2017 Apr 21.

8.

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.

J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.

PMID:
26314218
9.

Association between circadian gene CLOCK and cisplatin resistance in ovarian cancer cells: A preliminary study.

Xu H, Wang Z, Mo G, Chen H.

Oncol Lett. 2018 Jun;15(6):8945-8950. doi: 10.3892/ol.2018.8488. Epub 2018 Apr 13.

10.

Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.

Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Köhler-Vargas N, Lage H, Gansbacher B, Holm PS.

Hum Gene Ther. 2006 Jan;17(1):55-70.

PMID:
16409125
11.

Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.

Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH, Park BW, Yun CO.

Hum Gene Ther. 2006 Apr;17(4):379-90.

PMID:
16610926
12.

Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.

Henkels KM, Turchi JJ.

Cancer Res. 1999 Jul 1;59(13):3077-83. Erratum in: Cancer Res 2000 Feb 15;60(4):1150.

13.

The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines.

Kim MG, Pak JH, Choi WH, Park JY, Nam JH, Kim JH.

J Gynecol Oncol. 2012 Jul;23(3):182-9. doi: 10.3802/jgo.2012.23.3.182. Epub 2012 Jul 2.

14.

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.

Weberpals JI, O'Brien AM, Niknejad N, Garbuio KD, Clark-Knowles KV, Dimitroulakos J.

Cancer Cell Int. 2011 Aug 19;11(1):29. doi: 10.1186/1475-2867-11-29.

15.

Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.

Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, Murph MM, Govindarajan R, Eblen ST, Greer SF, Hooks SB.

PLoS One. 2013;8(3):e60185. doi: 10.1371/journal.pone.0060185. Epub 2013 Mar 22.

16.

[Enhancive effect of histone deacetylase inhibitor trichostatin a on transfection efficiency of adenovirus in ovarian carcinoma cell line A2780].

Chen G, Wang BB, Li FJ, Liu DY, Zhou JF, Lu YP, Ma D.

Ai Zheng. 2005 Oct;24(10):1196-200. Chinese.

PMID:
16219132
17.

Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.

Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EY, Dowson S, Webber L, Khan I, Ennis D, Syed N, Crook TR, Brenton JD, Lockley M, McNeish IA.

Mol Oncol. 2015 Apr;9(4):791-805. doi: 10.1016/j.molonc.2014.12.007. Epub 2014 Dec 29.

18.

Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line.

Zhang X, Jiang SJ, Shang B, Jiang HJ.

Thorac Cancer. 2015 Mar;6(2):202-8. doi: 10.1111/1759-7714.12167. Epub 2015 Mar 2.

19.

Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.

Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL.

Clin Cancer Res. 2000 Aug;6(8):3342-53.

20.

Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells.

Ma YY, Lin H, Moh JS, Chen KD, Wang IW, Ou YC, You YS, Lung CC.

Taiwan J Obstet Gynecol. 2011 Jun;50(2):165-71. doi: 10.1016/j.tjog.2011.01.022.

Supplemental Content

Support Center